博瑞医药(688166.SH)：拟放弃对参股公司增资扩股优先认购权

Core Viewpoint - 博瑞医药's subsidiary, Shenzhen Aoli Biotechnology Co., Ltd., is planning a capital increase, with the company relinquishing its preemptive rights, resulting in a decrease in its ownership stake from 30.1664% to 24.420458% [1] Group 1 - The capital increase involves an investment of RMB 25 million from Suzhou Hongbo Phase II Investment Partnership and RMB 55 million from other investors, including Suzhou Dongwu Industrial Merger Guidance Fund [1] - Following the capital increase, 博瑞医药's ownership in 奥礼生物 will be reduced significantly, indicating a dilution of its stake [1]